Vifor Pharma to acquire Sanifit, a clinical-stage cardio-renal biopharmaceutical company focused on treatments for progressive vascular calcification disorders, complementing and strengthening the Group’s growing nephrology portfolio. Sanifit, based in Palma (Spain) has had the backing of international and Spanish funds, among which are the CataloniaBio  & HealthTech members Alta Life Sciences, Ysios Capital and Healthequity, as well as Caixa Capital Risc, Columbus Venture Partners, and Innvierte from CDTI.

Under the terms of the acquisition agreement, Vifor Pharma will acquire 100% of the outstanding shares in Sanifit Therapeutics, receiving full global rights for SNF472, further enhancing the company’s portfolio of ...

Devicare has signed a participative loan worth €2 million from the Innova Global line by Avançsa, assigned to the Business and Expertise Department, with the option to convert the investment into Series A stock in the mid-term.

With this new economic injection, Devicare will continue the strategic development plan of new medical solutions under the Remote Patient Monitoring concept, which simply and economically places patients at the centre of their own healthcare management, known as patient empowerment, as well as the corresponding clinical studies and trials for the expansion throughout the European and North American markets. Currently, the company has ...

Cebiotex, a CataloniaBio member, has launched a new crowdequity campaign to raise €650,000 through CapitalCell in order to ensure its first drug, CEB-01 for post-op treatment of soft-tissue sarcomas, reaches paediatric oncology.

The campaign is part of a €1.6-million round of funding. The biotech firm hopes this capital will be covered with public and private funds, allowing it to begin phase I/II clinical trials on candidate CEB-01 with 15 patients in 2018, and begin proof-of concept testing for new oncology treatments for pancreatic cancer, liver cancer and brain tumours. “The first licences are expected from 2021, with ...

Genesis Biomed, a CataloniaBio member, was presented yesterday Genesis Ventures, a new investment fund located in Barcelona 

Vytrus Biotech, a CataloniaBio member, has raised more than €600,000 in a capital increase it closed on 29 October. This investment came through a crowdequity campaign on the Capital Cell platform.

Specifically, the biotechnology firm raised 110% of its initial goal of €550,000 and has become one of the first companies in Spain to raise over half a million euros through this type of campaign.

The investment will go towards boosting the company’s industrial growth and research lines, as well as helping prepare the company to go public next year.

Vytrus has distribution deals in more than ...